OKYO Pharma Ltd (OKYO) stock
OKYONasdaqBiological Products, (No Diagnostic Substances)
$1.40−0.02 (-1.41%)
Close on Nov 12, 2026Market cap $73.47MP/E –Yield –
OKYO Pharma EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2026 it was -$0.24. The highest annual figure on record is -$0.12 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$0.24 | – |
| FY2025 | Mar 31, 2025 | -$0.12 | – |
| FY2024 | Mar 31, 2024 | -$0.57 | – |
| FY2023 | Mar 31, 2023 | -$0.61 | – |
| FY2022 | Mar 31, 2022 | -$0.36 | – |
| FY2021 | Mar 31, 2021 | -$0.32 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?